CAJ | 학술논문

目的：探讨急性一氧化碳（CO）中毒早期使用神经节苷脂（GM-1）进行脑保护治疗对预防 CO 中毒后迟发性脑病（ delayed encephalopathy after acute carbon monoxide poisoning，DEACMP）的意义。方法选择我院急诊科收治的急性 CO中毒86例，随机分为观察组和对照组各43例。两组均在入院后即给予高压氧、改善微循环及营养神经等急性 CO中毒常规治疗，观察组在上述治疗基础上给予 GM-1治疗，观察比较两组住院时间、治疗效果、药物不良反应及治疗后2个月 DEACMP发生率。结果观察组住院时间短于对照组，治疗显效率及总有效率高于对照组，治疗后2个月 DEACMP发生率低于对照组，两组比较差异均有统计学意义（P ﹤0.05）。治疗过程中两组均未出现药物不良反应。结论急性 CO中毒早期使用 GM-1进行脑保护治疗，可提高总有效率，降低 DEACMP 发病率，且无明显不良反应。
목적：탐토급성일양화탄（CO）중독조기사용신경절감지（GM-1）진행뇌보호치료대예방 CO 중독후지발성뇌병（ delayed encephalopathy after acute carbon monoxide poisoning，DEACMP）적의의。방법선택아원급진과수치적급성 CO중독86례，수궤분위관찰조화대조조각43례。량조균재입원후즉급여고압양、개선미순배급영양신경등급성 CO중독상규치료，관찰조재상술치료기출상급여 GM-1치료，관찰비교량조주원시간、치료효과、약물불량반응급치료후2개월 DEACMP발생솔。결과관찰조주원시간단우대조조，치료현효솔급총유효솔고우대조조，치료후2개월 DEACMP발생솔저우대조조，량조비교차이균유통계학의의（P ﹤0.05）。치료과정중량조균미출현약물불량반응。결론급성 CO중독조기사용 GM-1진행뇌보호치료，가제고총유효솔，강저 DEACMP 발병솔，차무명현불량반응。
Objective To investigate the significance of ganglioside(GM-1)in cerebral protective therapy of delayed encephalopathy after acute carbon monoxide poisoning( DEACMP)in early period of acute carbon monoxide( CO)poisoning. Methods A total of 86 patients with acute CO poisoning were randomly divided into control group(n =43)and treatment group(n=43). Conventional treatments of hyperbaric oxygen,microcirculation improvement and trophic nerve were given to the two groups,and the treatment group was added with GM-1 based on the treatments. The length of hospital stay,treatment effectiveness and drug adverse reaction in the two groups were observed,and incidence rates of DEACMP 2 weeks after treat-ments were also observed. Results In the treatment group,the length of stay was shorter,the total effective rate was higher, and incidence rate of DEACMP 2 weeks after treatments was lower than those in control group,and the differences were statis-tically significant(P﹤0. 05). There was no drug adverse reaction during the treatments in the two groups. Conclusion Early use of GM-1 in cerebral protective therapy of acute CO poisoning can improve the total effective rate and reduce the incidence rate of DEACMP without obvious adverse reactions. .